Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Risperidone in Generalized Anxiety Disorder
NCT00086112Phase 3Completed
- Sponsor
- Johnson & Johnson
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Risperidone with Placebo (2 arms). Primary endpoint: Patient-Rated Troubling Symptoms for Anxiety at 6 weeks. Status: completed.
02
Drugs
risperidone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00086112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086112.